Long-acting response of COX-2-mediated metastasis inhibition by oxaliplatin-based CP-L-OHP-Reference-Cited by-同舟云学术

Long-acting response of COX-2-mediated metastasis inhibition by oxaliplatin-based CP-L-OHP

Published:2022 Issue:22 Volume:46 Page:10637-10643
ISSN:1144-0546
Container-title:New Journal of Chemistry
language:en
Short-container-title:New J. Chem.

Author:

Hu Juan-Juan¹,Ma Zhong-Ying¹,He Xin-Rui¹,Wu Yi-Gang¹,Chen Qian¹,Song Xue-Qing¹,Wang Guan-Yuan¹,Li Yi-Han¹,Xu Jing-Yuan¹²^ORCID

Affiliation:

1. Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China

2. Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, Tianjin Medical University, Tianjin, 300070, China

Abstract

Among four oxaliplatin-based Pt(iv) complexes, CP-L-OHP significantly delayed BGC-823 cell metastasis via long-acting inhibition of COX-2.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hebei Province

Tianjin Science and Technology Committee

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,General Chemistry,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2022/NJ/D2NJ01196D

Reference48 articles.

1. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer

2. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

3. Long-Term Mortality after Gastric Bypass Surgery

4. Nutritional deficiency post esophageal and gastric cancer surgery: A quality improvement study

5. Gastric cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116;RSC Medicinal Chemistry;2024